Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (June 2025)
33 slides from Cytosorbents's investor presentation, June 2025
Slide 1: Investor Presentation June 2025
NASDAQ: CTSO Investor Presentation June 2025 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin disposable “razorblade” that is “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology CytoSorb • Tre
Slide 4: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 5: Expanding the Dimension of Blood Purification
Expanding the Dimension of Blood Purification CytoSorb removes a broad range of harmful substances that dialysis does not CytoSorb works like the liver Dialysis works like the kidney Large Molecules and Fat soluble substances Small Molecules and Water soluble substances Cytokines Inflammatory mediat
Slide 6: Products are “Plug and Play” Compatible
Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today CytoSorbents PuriFi Pump Dialysis or CRRT Hemoperfusion (Continuous Renal Replacement Therapy) (Standalone Treatment) Launched Q2 2024 CytoSorbents launched its PuriFi pump, an easy-to-use h
Slide 7: CytoSorb: Our Core Business
CytoSorb Our Core Business 7 |
Slide 8: CytoSorb Targets Massive Inflammation - the Heart of Critical Illness
CytoSorb Targets Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE S
Slide 9: Inflammation Affects Up to 60% of ICU Patients
Inflammation Affects Up to 60% of ICU Patients Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory High risk surg
Slide 10: CytoSorb Integrated Approach for Critical Care
CytoSorb Integrated Approach for Critical Care Right Break the Cycle Patient of Deadly Inflammation Highest Chance for Reverse Good Instability Clinical Outcome Right Right Timing Dose Restore and Preserve Organ Function Just like antibiotics… Treat early, treat aggressively, & complete the full cou
Slide 11: 2025: COSMOS Registry Highlights Treatment Strategy Success
2025: COSMOS Registry Highlights Treatment Strategy Success COSMOS registry, patient characteristics CAPILLARY LUNG • Data from 150 patients analyzed SHOCK LEAK FUNCTION • Critical care indications: Septic shock (57.6%) Cardiogenic shock (12.9%) Rhabdomyolysis (10.6%) Acute/acute-on-chronic liver fa
Slide 12: 2025: Early and Intensive Treatment with More Blood Treated Works Best
2025: Early and Intensive Treatment with More Blood Treated Works Best 12 |
Slide 13: 2025: First Meta-Analysis in Septic Shock
2025: First Meta-Analysis in Septic Shock Septic shock is a dreaded complication of sepsis resulting in a potentially lethal drop in blood pressure with a high expected mortality. CytoSorb can reverse shock and reduce mortality • 2025 Meta-analysis is the first to specifically investigate the use of
Slide 14: The Opportunity of DrugSorb-ATR
The Opportunity of 14 | * The DrugSorb-ATR system is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 15: Large Unmet Need for Blood Thinner Reversal
Large Unmet Need for Blood Thinner Reversal Millions of people worldwide are on Anti-thrombotic blood thinners to reduce risk of heart attack and stroke Brilinta® (ticagrelor) Eliquis® (apixaban) Xarelto® (rivaroxaban) (AstraZeneca) (Pfizer, BMS) (Bayer, Jansenn/J&J) Acute Coronary Syndrome, Atrial
Slide 16: Cardiac Surgery and Bleeding Risk
Cardiac Surgery and Bleeding Risk Bleeding at baseline varies according to type of cardiothoracic surgery without the use of antithrombotic drugs Isolated CABG without blood Factors associated with bleeding: thinners: • Type of Surgery ~5% Major Bleeding • Surgical duration Re-operation 1/300 • Dura
Slide 17: Brilinta Increases Bleeding Risk in Isolated CABG Surgery
Brilinta Increases Bleeding Risk in Isolated CABG Surgery The European Multicenter Study on CABG (E-CABG) Registry is one of the largest real-world data registries evaluating outcomes in CABG patients – the most common cardiac surgery • In this E-CABG registry study, the incidence of severe or massi
Slide 18: DrugSorb-ATR is an FDA Breakthrough Device
DrugSorb-ATR is an FDA Breakthrough Device • DrugSorb-ATR is an investigational device that uses an equivalent polymer technology to CytoSorb and installs easily into a cardiopulmonary bypass machine * • As whole blood is pumped through the cartridge, it is designed to remove free drug during surger
Slide 19: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without X X XX X delay, while reducing or preventing 19 | bleeding complications
Slide 20: The Pivotal STAR-T RCT
The Pivotal STAR-T RCT In the U.S. & Canadian 140-patient pivotal STAR-T RCT evaluating the safety and efficacy of DrugSorb-ATR to reduce the severity of perioperative bleeding in cardiac surgery patients when used within 2 days of Brilinta (ticagrelor, AstraZeneca) discontinuation, the Principal In
Slide 21: STAR Registry: Real World Evidence
STAR Registry: Real World Evidence • STAR Registry now in 6 countries (GER, UK, BEL, AUT, SWE, CH) with 600+ subjects enrolled in different cardiac surgeries • Ticagrelor removal in 102 CABG patients now published • Ticagrelor removal in an updated cohort of 150 CABG patients presented in Paris at E
Slide 22: Data from Updated Cohort of CABG Patients Presented at EuroPCR
Data from Updated Cohort of 150 CABG Patients Presented at EuroPCR Two real-world cohorts of patients on ticagrelor undergoing isolated on-pump CABG before completing the recommended washout were compared: ➢ No intraoperative ticagrelor removal - Control (n=644)# ➢ Intraoperative ticagrelor removal
Slide 23: Statistically and Clinically Significant Impact on Bleeding
Statistically and Clinically Significant Impact on Bleeding Bleeding Transfusions Revisions 40.0% p<0.001 p<0.001 p=0.02 35.0% Control 33.0% 30.0% Device 25.0% 27.0% ↓68% ➢ No significant difference in: 20.0% o 24-h CTD > 2L (7.1% vs. 6.5%) ↓78% o 30-day mortality (6.5% vs. 4.4%) 15.0% ➢ 0 device-re
Slide 24: FDA and Health Canada Regulatory Update
FDA and Health Canada Regulatory Update • FDA De Novo submission and Medical Device License application to Health Canada included STAR-T RCT data and STAR registry real world evidence (RWE) • Interactive review with FDA resolved many issues, however, a denial letter was issued April 25, 2025 • Subse
Slide 25: Pre-Launch Activities are Underway
Pre-Launch Activities are Underway Engaging with U.S. and Developing a clear value Recruiting marketing, sales, Canadian key opinion leaders proposition for surgeons, and medical talent (KOLs) hospitals, and patients Preparing traditional and Building awareness and Managing numerous market digital m
Slide 26: DrugSorb-ATR is a Potential Win for All Stakeholders
DrugSorb-ATR is a Potential Win for All Stakeholders Patients ✓ Minimize delays to definitive surgery ✓ Reduce serious bleeding risk, which is associated with longer hospital stays and increased morbidity and mortality Surgeons ✓ No change in workflow, seamless integration into heart-lung machine ✓
Slide 27: Strong Value Proposition for Hospitals
Strong Value Proposition for Hospitals Waiting in the hospital for multiple days for the drug to “washout” is highly problematic: • Exposes patients to added risk due to the delay of having the needed operation • Increases hospital costs and reduces efficiency by blocking beds and reducing throughpu
Slide 28: Large Total Addressable Market
Large Total Addressable Market Future Opportunity $1+ Billion Near-Term Opportunity >$600M >$200M >$150M >$450M >$450M Initial Opportunity >$300M • U.S. & CAN Ticagrelor Removal in CABG • DOAC Removal in CABG • DOAC Removal in Hospital-Wide Applications • Expansion of U.S. & CAN • U.S. & CAN Ticagre
Slide 29: Financial Performance
29 Financial Performance CytoSorbents.
Slide 30: Annual Product Sales
Annual Product Sales CytoSorbents sells through Direct Sales in 15 countries and Distributors in 60+ others Recent Financial Performance $45.0 Annual Product Sales FY2024 1Q25 $39.5M $40.1M $40.0 $6.3 $9.4 $35.0 $35.6M Revenue $35.6m $8.7m $35.6 $33.8 $31.1M* $30.0 $29.4M* Growth % 15% (3%) / 0%** $
Slide 31: Strengthened Balance Sheet with Goal to Drive Core Business to Cash-Flow Break-even in 2H 2025
Strengthened Balance Sheet with Goal to Drive Core Business to Cash-Flow Break-even in 2H 2025 • $6.8 million received from successful Rights Offering in Q1 2025 • Provided $6.8 million, net of fees, to date • Released $5.0 million of restricted cash • Together increased net liquidity of $11.8 milli
Slide 32: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition CytoSorb is an established, international core business in critical care and cardiac surgery with $35M+ in high margin product sales with expectations for growth due to: • Significant market opportunity, targeting major unmet medical needs • “Right patient at
Slide 33: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com 908-307-0367 www.cytosorbents.com 33